Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, CD20/immunology , BNT162 Vaccine/administration & dosage , COVID-19 Drug Treatment , Lymphoma, B-Cell/immunology , Lymphoma, Non-Hodgkin/immunology , SARS-CoV-2/immunology , Aged , Aged, 80 and over , COVID-19/immunology , COVID-19/virology , Female , Follow-Up Studies , Humans , Lymphoma, B-Cell/blood , Lymphoma, B-Cell/drug therapy , Lymphoma, B-Cell/virology , Lymphoma, Non-Hodgkin/blood , Lymphoma, Non-Hodgkin/drug therapy , Lymphoma, Non-Hodgkin/virology , Male , PrognosisSubject(s)
COVID-19/complications , COVID-19/therapy , Lymphoma, Non-Hodgkin/complications , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , COVID-19/immunology , Cell Culture Techniques , Clinical Decision-Making , Female , Humans , Immunity, Cellular/drug effects , Immunity, Humoral/drug effects , Immunocompromised Host , Immunotherapy , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/therapy , SARS-CoV-2/immunology , SARS-CoV-2/isolation & purification , Secondary PreventionSubject(s)
COVID-19 Vaccines/pharmacology , Hematologic Neoplasms/immunology , 2019-nCoV Vaccine mRNA-1273 , Adult , Aged , Aged, 80 and over , Antibody Formation , BNT162 Vaccine , COVID-19 Vaccines/immunology , Female , Hematologic Neoplasms/therapy , Humans , Immunization, Secondary , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Spike Glycoprotein, Coronavirus/immunology , Waldenstrom Macroglobulinemia/immunology , Waldenstrom Macroglobulinemia/therapySubject(s)
Antibodies, Neutralizing/blood , Antibodies, Viral/blood , BNT162 Vaccine/immunology , COVID-19/prevention & control , Immunoglobulin G/blood , SARS-CoV-2/immunology , Aged , Antibodies, Neutralizing/biosynthesis , Antibodies, Viral/biosynthesis , Cohort Studies , Female , Hematologic Neoplasms/immunology , Humans , Immunogenicity, Vaccine , Immunoglobulin G/biosynthesis , Kinetics , Leukemia/immunology , Lymphoma, Non-Hodgkin/immunology , Male , Middle Aged , Multiple Myeloma/immunology , Myeloproliferative Disorders/immunology , Time Factors , VaccinationSubject(s)
Antibodies, Viral/biosynthesis , BNT162 Vaccine/immunology , COVID-19/prevention & control , Immunoglobulin G/biosynthesis , Immunotherapy, Adoptive , SARS-CoV-2/immunology , Adult , Aged , Antigens, Viral/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , BNT162 Vaccine/adverse effects , Biological Products/therapeutic use , Combined Modality Therapy , Female , Fever/etiology , Hematopoietic Stem Cell Transplantation , Humans , Immunization, Secondary , Immunocompromised Host , Immunogenicity, Vaccine , Lymphoma, Non-Hodgkin/immunology , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Pain/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Receptors, Antigen, T-Cell/therapeutic use , Receptors, Chimeric Antigen/therapeutic use , Spike Glycoprotein, Coronavirus/immunology , Vaccination , Young AdultABSTRACT
Recent studies have shown that persistent SARS-CoV-2 infections in immunocompromised patients can trigger the accumulation of an unusual high number of mutations with potential relevance at both biological and epidemiological levels. Here, we report a case of an immunocompromised patient (non-Hodgkin lymphoma patient under immunosuppressive therapy) with a persistent SARS-CoV-2 infection (marked by intermittent positivity) over at least 6 months. Viral genome sequencing was performed at days 1, 164, and 171 to evaluate SARS-CoV-2 evolution. Among the 15 single-nucleotide polymorphisms (SNPs) (11 leading to amino acid alterations) and 3 deletions accumulated during this long-term infection, four amino acid changes (V3G, S50L, N87S, and A222V) and two deletions (18-30del and 141-144del) occurred in the virus Spike protein. Although no convalescent plasma therapy was administered, some of the detected mutations have been independently reported in other chronically infected individuals, which supports a scenario of convergent adaptive evolution. This study shows that it is of the utmost relevance to monitor the SARS-CoV-2 evolution in immunocompromised individuals, not only to identify novel potentially adaptive mutations, but also to mitigate the risk of introducing "hyper-evolved" variants in the community. IMPORTANCE Tracking the within-patient evolution of SARS-CoV-2 is key to understanding how this pandemic virus shapes its genome toward immune evasion and survival. In the present study, by monitoring a long-term COVID-19 immunocompromised patient, we observed the concurrent emergence of mutations potentially associated with immune evasion and/or enhanced transmission, mostly targeting the SARS-CoV-2 key host-interacting protein and antigen. These findings show that the frequent oscillation in the immune status in immunocompromised individuals can trigger an accelerated virus evolution, thus consolidating this study model as an accelerated pathway to better understand SARS-CoV-2 adaptive traits and anticipate the emergence of variants of concern.
Subject(s)
COVID-19/immunology , Immune Evasion/immunology , Immunocompromised Host/immunology , Lymphoma, Non-Hodgkin/immunology , SARS-CoV-2/immunology , Amino Acids/genetics , Amino Acids/immunology , Animals , COVID-19/virology , Cell Line , Chlorocebus aethiops , Female , Genome, Viral/genetics , Genome, Viral/immunology , Humans , Immune Evasion/genetics , Immunization, Passive/methods , Lymphoma, Non-Hodgkin/virology , Middle Aged , Mutation/genetics , Mutation/immunology , Pandemics/prevention & control , SARS-CoV-2/genetics , Vero Cells , Virus Replication/genetics , Virus Replication/immunologyABSTRACT
BACKGROUND This is a case report of an immunocompromised patient with a history of non-Hodgkin lymphoma and persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection who was seronegative and successfully treated with convalescent plasma. CASE REPORT A 63-year-old woman with a past medical history of non-Hodgkin lymphoma in remission while on maintenance therapy with the anti-CD20 monoclonal antibody, obinutuzumab, tested positive for SARS-CoV-2 via nasopharyngeal reverse transcription polymerase chain reaction (RT-PCR) testing over 12 weeks and persistently tested seronegative for immunoglobulin G (IgG) antibodies using SARS-CoV-2 IgG chemiluminescent microparticle immunoassay technology. During this time, the patient experienced waxing and waning of symptoms, which included fever, myalgia, and non-productive cough, but never acquired severe respiratory distress. She was admitted to our hospital on illness day 88, and her symptoms resolved after the administration of convalescent plasma. CONCLUSIONS As the understanding of the pathogenesis of SARS-CoV-2 continues to evolve, we can currently only speculate about the occurrence of chronic infection vs. reinfection. The protective role of antibodies and their longevity against SARS-CoV-2 remain unclear. Since humoral immunity has an integral role in SARS-CoV-2 infection, various phase 3 vaccine trials are underway. In the context of this pandemic, the present case demonstrates the challenges in our understanding of testing and treating immunocompromised patients.